title: Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis.
abstract: OBJECTIVE
  To investigate whether low ganciclovir serum levels in patients on maintenance oral ganciclovir therapy are associated with recurrence of CMV retinitis.
  
  
  METHODS
  A prospective study of the plasma concentration of ganciclovir after initiation of maintenance oral ganciclovir therapy in 14 AIDS patients who had recovered from acute cytomegalovirus (CMV) retinitis.
  
  
  RESULTS
  Five of the 14 patients exhibited a mean time to recurrence of 37 days. The mean trough plasma concentration of ganciclovir in these patients after 1 month of oral ganciclovir therapy, was 0.40 +/- 0.30 mg/L. Nine patients had a mean time of progression of 263 days. The mean trough plasma concentration of ganciclovir in the latter patients was 0.80 +/- 0.60 mg/L.
  
  
  CONCLUSIONS
  Patients exhibiting trough plasma levels of ganciclovir below 0.6 mg/L may be at higher risk of progression than patients who exhibited levels above 0.6 mg/L.
authors.affiliation: Department of Immunologie Clinique-INSERM U 430, Hôpital Broussais, Paris, France. christophe.piketty@brs.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Piketty
authors.forename: C
authors.initials: C
authors.lastname: Bardin
authors.forename: J
authors.initials: J
authors.lastname: Gilquin
authors.forename: A
authors.initials: A
authors.lastname: Gairard
authors.forename: M D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: F
authors.initials: F
authors.lastname: Chast
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000097:blood* / Q000150:complications / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications* / Q000821:virology; D000208:Acute Disease; D000284:Administration, Oral; D000998:Antiviral Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000187:drug effects; D017726:Cytomegalovirus Retinitis / Q000097:blood* / Q000150:complications / Q000517:prevention & control; D004351:Drug Resistance; D015774:Ganciclovir / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D011446:Prospective Studies; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir